# US 2024/0309095 A1 · Anti-b7-h4 antibodies and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0309095 A1
- Document ID: US20240309095A1
- Status: Published application
- Kind: A1
- Application number: 18/576,936
- Filed: 2022-07-07
- Published: 2024-09-19
- Earliest claimed: 2021-07-07
- Assignees: Incyte Corporation; Specifica Inc.
- Applicants: Incyte Corporation; Specifica Inc.
- Inventors: Fortunato Ferrara; Michael Frank Erasmus; Andre Azevedo Reis Teixeira; Andrew Raymon Morton Bradbury
- Web page: https://patentgrep.com/patent/US20240309095A1

## CPC

- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Anti-B7-H4 antibodies are disclosed. Also disclosed are related nucleic acids, vectors, cells, kits, and pharmaceutical compositions. Methods of treating cancer with the anti-B7-H4 antibodies are also disclosed.

## Claims

### Claim 1

An antibody that binds to human B7-H4, wherein the antibody comprises a light chain variable region (VL) comprising a VL CDR1, a VL CDR2, and a VL CDR3, wherein:
the VL CDR1 comprises the amino acid sequence of any one of SEQ ID NOs:1-12;
the VL CDR2 comprises the amino acid sequence of any one of SEQ ID NOs:13-17;
the VL CDR3 comprises the amino acid sequence of any one of SEQ ID NOs:18-22;
the VH CDR1 comprises the amino acid sequence of any one of SEQ ID NOs:23-43;
the VH CDR2 comprises the amino acid sequence of any one of SEQ ID NOs:44-89;
and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90.

### Claim 2 (depends on 1)

The antibody of claim 1, wherein the VL CDR1, the VL CDR2, and the VL CDR3 each correspond to the VL CDRs set forth in Table 4 for a single VL clone, and wherein the VH CDR1, the VH CDR2, and the VH CDR3 each correspond to the VH CDRs set forth in Table 4 for a single VH clone.

### Claim 3 (depends on 1)

The antibody of claim 1, wherein;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO: 1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:18; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:23; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:44; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO.1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:24; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:45; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:25; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:46; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO: 1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:26; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:47; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:27; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:48; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:2; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:28; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:49; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:18; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:26; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:50; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:28; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:51; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:26; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:52; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:26; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:53; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:26; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:50; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:18; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:29; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:54; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:3; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:18; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:30; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:46; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:3; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:14; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:18; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:26; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:50; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:4; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:28; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:55; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:5; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:31; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:56; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:6; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:32; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:49; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:7; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:24; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:45; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO: 1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:28; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:45; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:30; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:57; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:27; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:58; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:20; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:33; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:59; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:25; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:60; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO: 1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:30; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:61; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:29; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:54; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:34; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:62; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:30; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:63; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:28; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:64; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:8; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:15; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:18; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:26; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:50; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:18; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:26; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:65; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:9; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:18; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:31; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:66; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:3, the VL CDR2 comprises the amino acid sequence of SEQ ID NO:14; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:35; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:46; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO: 1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:36; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:51; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:34; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:67; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:34; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:51; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:33; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:68; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:21; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:27; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:65; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:18; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:37; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:60; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:4; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:30; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:69; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:16; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:31; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:70; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:8; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:15; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:33; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:59; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:18; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:26; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:64; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:27; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:71; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO: 1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:33; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:48; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO: 1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:30; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:72; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:2; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:15; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:18; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:26; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:73; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:24; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:74; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:26; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:75; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:28; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:66; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:9; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:30; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:76; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:38; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:75; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:8; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:15; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:26; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:65; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:39; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:76; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:40; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:66; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:34; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:77; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:34; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:60; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:30; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:78; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:8; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:15; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:18; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:26; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:79; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO: 1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:29; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:46; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:26; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:80; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:5; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:41; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:60; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:32; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:58; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:22; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:34; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:76; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO: 1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:30; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:81; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:4; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:40; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:60; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:28; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:82; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:34; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:75; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:26; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:83; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:4; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:29; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:84; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:10; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:25; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:62; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:2; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:42; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:76; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:11; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:17; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:18; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:26; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:50; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:5; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:29; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:85; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:40; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:46; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:27; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:62; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:30; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:86; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:25; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:62; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:10; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:34; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:62; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO: 1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:34; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:58; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:12; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:43; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:75; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:34; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:87; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90; or
the VL CDR1 comprises the amino acid sequence of SEQ ID NO:1; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:19; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:30; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:88; and the VH CDR3 comprises the amino acid sequence of SEQ ID NO:90.

### Claim 4 (depends on 1)

The antibody of claim 1, wherein
the VL comprises the amino acid sequence of any one of SEQ ID NOs:96-118; and
the VH comprises the amino acid sequence of any one of SEQ ID NOs:119-190.

### Claim 5 (depends on 1)

The antibody of claim 1, wherein;
the VL comprises the amino acid sequence of SEQ ID NO:96 and the VH comprises the amino acid sequence of SEQ ID NO:119;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:120;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:121;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:122;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:123;
the VL comprises the amino acid sequence of SEQ ID NO:98 and the VH comprises the amino acid sequence of SEQ ID NO:124;
the VL comprises the amino acid sequence of SEQ ID NO:96 and the VH comprises the amino acid sequence of SEQ ID NO:125;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:126;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:127;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:128;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:125;
the VL comprises the amino acid sequence of SEQ ID NO:96 and the VH comprises the amino acid sequence of SEQ ID NO:129;
the VL comprises the amino acid sequence of SEQ ID NO:99 and the VH comprises the amino acid sequence of SEQ ID NO:130;
the VL comprises the amino acid sequence of SEQ ID NO:100 and the VH comprises the amino acid sequence of SEQ ID NO:125;
the VL comprises the amino acid sequence of SEQ ID NO:101 and the VH comprises the amino acid sequence of SEQ ID NO:131;
the VL comprises the amino acid sequence of SEQ ID NO:102 and the VH comprises the amino acid sequence of SEQ ID NO:132;
the VL comprises the amino acid sequence of SEQ ID NO: 103 and the VH comprises the amino acid sequence of SEQ ID NO:133;
the VL comprises the amino acid sequence of SEQ ID NO:104 and the VH comprises the amino acid sequence of SEQ ID NO:120;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:134;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:135;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:136;
the VL comprises the amino acid sequence of SEQ ID NO:105 and the VH comprises the amino acid sequence of SEQ ID NO:137;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:138;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:139;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:129;
the VL comprises the amino acid sequence of SEQ ID NO:106 and the VH comprises the amino acid sequence of SEQ ID NO:125;
the VL comprises the amino acid sequence of SEQ ID NO:96 and the VH comprises the amino acid sequence of SEQ ID NO:140;
the VL comprises the amino acid sequence of SEQ ID NO:107 and the VH comprises the amino acid sequence of SEQ ID NO:141;
the VL comprises the amino acid sequence of SEQ ID NO:108 and the VH comprises the amino acid sequence of SEQ ID NO:142;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:143;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:144;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:145;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:146;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:147;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:148;
the VL comprises the amino acid sequence of SEQ ID NO:96 and the VH comprises the amino acid sequence of SEQ ID NO:149;
the VL comprises the amino acid sequence of SEQ ID NO:101 and the VH comprises the amino acid sequence of SEQ ID NO:150;
the VL comprises the amino acid sequence of SEQ ID NO:109 and the VH comprises the amino acid sequence of SEQ ID NO:151;
the VL comprises the amino acid sequence of SEQ ID NO:110 and the VH comprises the amino acid sequence of SEQ ID NO:137;
the VL comprises the amino acid sequence of SEQ ID NO:96 and the VH comprises the amino acid sequence of SEQ ID NO:152;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:153;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:154;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:155;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:156;
the VL comprises the amino acid sequence of SEQ ID NO:111 and the VH comprises the amino acid sequence of SEQ ID NO:157;
the VL comprises the amino acid sequence of SEQ ID NO:112 and the VH comprises the amino acid sequence of SEQ ID NO:158;
the VL comprises the amino acid sequence of SEQ ID NO: 113 and the VH comprises the amino acid sequence of SEQ ID NO:159;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:160;
the VL comprises the amino acid sequence of SEQ ID NO:110 and the VH comprises the amino acid sequence of SEQ ID NO:140;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:161;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:162;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:163;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:164;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:165;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:166;
the VL comprises the amino acid sequence of SEQ ID NO:106 and the VH comprises the amino acid sequence of SEQ ID NO:167;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:168;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:169;
the VL comprises the amino acid sequence of SEQ ID NO:102 and the VH comprises the amino acid sequence of SEQ ID NO:170;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:171;
the VL comprises the amino acid sequence of SEQ ID NO:114 and the VH comprises the amino acid sequence of SEQ ID NO:172;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:173;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:174;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:175;
the VL comprises the amino acid sequence of SEQ ID NO:101 and the VH comprises the amino acid sequence of SEQ ID NO:176;
the VL comprises the amino acid sequence of SEQ ID NO:101 and the VH comprises the amino acid sequence of SEQ ID NO:177;
the VL comprises the amino acid sequence of SEQ ID NO:115 and the VH comprises the amino acid sequence of SEQ ID NO:178;
the VL comprises the amino acid sequence of SEQ ID NO:98 and the VH comprises the amino acid sequence of SEQ ID NO:179;
the VL comprises the amino acid sequence of SEQ ID NO:116 and the VH comprises the amino acid sequence of SEQ ID NO:125;
the VL comprises the amino acid sequence of SEQ ID NO:102 and the VH comprises the amino acid sequence of SEQ ID NO:180;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:181;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:182;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:183;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:184;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:185;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:186;
the VL comprises the amino acid sequence of SEQ ID NO: 117 and the VH comprises the amino acid sequence of SEQ ID NO:145;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:187;
the VL comprises the amino acid sequence of SEQ ID NO:118 and the VH comprises the amino acid sequence of SEQ ID NO:188;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:189;
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:190; or
the VL comprises the amino acid sequence of SEQ ID NO:97 and the VH comprises the amino acid sequence of SEQ ID NO:178.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The antibody of any one of claims 1-5, wherein the antibody is a full-length antibody.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The antibody of any one of claims 1-6, wherein the antibody is a bispecific antibody, a single chain antibody (scFv), an Fab fragment, an F(ab′)2 fragment, an Fab′ fragment, an Fv fragment, an sc(Fv)2, or a diabody.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The antibody of any one of claims 1-7, which is conjugated to a toxic substance.

### Claim 9 (depends on 8)

The antibody of claim 8, wherein the toxic substance is a radioisotope or a cytotoxic agent.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The antibody of any one of claims 1-9, which is conjugated to a detectable label.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A nucleic acid or a set of nucleic acids, which collectively encodes the antibody of any one of claims 1-10.

### Claim 12 (depends on 11)

An expression vector or a set of expression vectors comprising the nucleic acid or the set of nucleic acids of claim 11 operably linked to a promoter.

### Claim 13 (depends on 11, 12)

An isolated cell comprising the nucleic acid or the set of nucleic acids of claim 11 or the expression vector or the set of expression vectors of claim 12.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 13)

A method of making the antibody of any one of claims 1-10, comprising culturing the cell of claim 13 and isolating the antibody.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A pharmaceutical composition comprising the antibody of any one of claims 1-10, the nucleic acid or the set of nucleic acids of claim 11, the expression vector or the set of expression vectors of claim 12, or the isolated cell of claim 13, and a pharmaceutically acceptable carrier.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15)

A method of treating a cancer in a human subject in need thereof, the method comprising administering to the human subject an effective amount of the antibody of any one of claims 1-10 or the pharmaceutical composition of claim 15.

### Claim 17 (depends on 16)

The method of claim 16, wherein the cancer is ovarian cancer, breast cancer, endometrial cancer, bladder cancer, esophageal cancer, oral squamous cell carcinoma, brain cancer, prostate cancer, pancreatic cancer, cervical cancer, skin cancer, lung cancer, gastric cancer, or renal cell carcinoma.

### Claim 18 (depends on 16, 17)

The method of claim 16 or claim 17, further comprising administering to the human subject an additional therapy selected from the group consisting of a Janus tyrosine kinase (JAK) inhibitor, a phosphoinositide 3-kinase (PI3K) inhibitor, a standard of care therapy, or a combination thereof.

### Claim 19 (depends on 18)

The method of claim 18, wherein the JAK inhibitor is ruxolitinib and itaticinib.

### Claim 20 (depends on 18)

The method of claim 18, wherein the PI3K inhibitor is parsaclisib.

### Claim 21 (depends on 18)

The method of claim 18, wherein the standard of care therapy is selected from the group consisting of a chemotherapy, a radiation therapy, a surgical therapy, an immunotherapy, or a combination thereof.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A method for detecting human B7-H4, the method comprising:
contacting the antibody of any one of claims 1-10 with a sample suspected of containing B7-H4, and
detecting binding of the antibody to B7-H4.

### Claim 23 (depends on 22)

The method of claim 22, wherein B7-H4 is expressed on a cell surface.

### Claim 24 (depends on 22, 23)

The method of claim 22 or claim 23, wherein the contacting step is performed by administering the antibody to a subject.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A kit comprising the antibody of any one of claims 1-10, the nucleic acid or the set of nucleic acids of claim 11, the expression vector or the set of expression vectors of claim 12, or the isolated cell of claim 13, and instructions for use in treating a cancer in a human subject in need thereof, optionally with instructions for use in combination with an additional therapy.
